(Total Views: 101)
Posted On: 09/19/2019 9:10:44 AM
Post# of 46527
$ISWH International Spirits & Wellness Holdings, Inc. (OTCMKTS: ISWH) (“ISWH” or the “Company”), a top-tier brand incubator in the Spirits, CBD-Infused Products, and Home Healthcare markets, is pleased to announce that sales of its hemp-derived CBD products are set to resume. Marketing and distribution will be coordinated through its strategic partner, BioPulse Labs (“BioPulse”), a market leader in CBD nano-infusion technology and ecommerce marketing and distribution.
“Growth estimates for the overall CBD market are in the process of being revised sharply higher as mainstream consumer adoption dramatically outperforms prior baseline expectations for 2019,” commented Terry Williams, ISWH CEO. “It’s a perfect time for our diverse array of hemp-derived CBD products to resume live sales and distribution. This is a principle reason we have had to mark up our financial expectations heading into Q4.”
The Company will be marketing P19 Nano-Infused CBD Tinctures, P19 vegan CBD Gummies, P19 CBD Pain Cream, P19 Nano Nectar CBD Drops, and P19 Flavored CBD Shooters. All products are nano-infused with CBD derived from hemp, which is fully legal in all 50 states. Nano-infusion ensures the highest possible bioavailability, which is particularly important given the powerful health and wellness applications for cannabidiol (CBD).
Management notes that the Company is eager to restart sales given recent upward adjustments to forecasts for growth in CBD demand over coming quarters. Brightfield Group, a leading market and consumer intelligence firm for the legal CBD and cannabis industries, recently increased its own growth forecast for the CBD market, published analysis calling for a 706% year-over-year CBD product sales jump in the US in 2019 to around $5 billion in total sales, with sales expected to reach $23.7 billion by 2023. Set to Resume Full-Scale CBD-based Product Sales as CBD Market Surges to $5B in 2019
https://www.globenewswire.com/news-release/20...-2019.html
“Growth estimates for the overall CBD market are in the process of being revised sharply higher as mainstream consumer adoption dramatically outperforms prior baseline expectations for 2019,” commented Terry Williams, ISWH CEO. “It’s a perfect time for our diverse array of hemp-derived CBD products to resume live sales and distribution. This is a principle reason we have had to mark up our financial expectations heading into Q4.”
The Company will be marketing P19 Nano-Infused CBD Tinctures, P19 vegan CBD Gummies, P19 CBD Pain Cream, P19 Nano Nectar CBD Drops, and P19 Flavored CBD Shooters. All products are nano-infused with CBD derived from hemp, which is fully legal in all 50 states. Nano-infusion ensures the highest possible bioavailability, which is particularly important given the powerful health and wellness applications for cannabidiol (CBD).
Management notes that the Company is eager to restart sales given recent upward adjustments to forecasts for growth in CBD demand over coming quarters. Brightfield Group, a leading market and consumer intelligence firm for the legal CBD and cannabis industries, recently increased its own growth forecast for the CBD market, published analysis calling for a 706% year-over-year CBD product sales jump in the US in 2019 to around $5 billion in total sales, with sales expected to reach $23.7 billion by 2023. Set to Resume Full-Scale CBD-based Product Sales as CBD Market Surges to $5B in 2019
https://www.globenewswire.com/news-release/20...-2019.html
(0)
(0)
